Delivery Order SPE2DB22D2007-SPE2DB25FJ0ZE
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,095.09 to AmerisourceBergen Drug Corp for the supply of Phenobarbital 130 mg/mL vials, with an ultimate completion date of July 21, 2025. This non-set-aside contract employs firm fixed pricing and represents a discrete purchase order under AmerisourceBergen's broader pharmaceutical supply arrangements with DLA. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $2,562.39 to AmerisourceBergen Drug Corp for Phenobarbital 130 mg/mL vials, with an ultimate completion date of September 18, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, is the prime contractor on this...
- The Defense Logistics Agency awarded a delivery order valued at $1,789.75 to AmerisourceBergen Drug Corp for the supply of Phenobarbital 130 mg/mL vials. This firm fixed-price, competitively awarded contract contains no set-aside designation and is scheduled for completion by July 1, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a routine pharmaceutical procurement supporting federal...
- The Defense Logistics Agency awarded a $1,095.09 delivery order to AmerisourceBergen Drug Corp for Phenobarbital 130 mg/ml vials, with an ultimate completion date of July 22, 2025. This non-set-aside, competitively awarded contract reflects a firm fixed price arrangement and represents a child order under AmerisourceBergen's larger federal contract vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor...
- The Defense Logistics Agency awarded a delivery order valued at $4,494.60 to AmerisourceBergen Drug Corp for the supply of Phenobarbital 65 mg/ml vials, with an ultimate completion date of April 8, 2025. This firm fixed price delivery order, awarded on April 7, 2025, was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Phenobarbital 130 mg/mL vials under a firm fixed-price contract. This award, valued at $1,287.42, represents a competitive delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $9,470.98 to AmerisourceBergen Drug Corp for the supply of Phenobarbital 130 mg/ml vials. The contract, awarded on August 5, 2025, with an ultimate completion date of August 6, 2025, utilizes firm fixed pricing with no set-aside designation. This delivery order represents a competitive award under AmerisourceBergen's existing federal contract portfolio and will be performed at the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Phenobarbital 130 mg/ml vials, with a contract ceiling value of $8,976.00 and an ultimate completion date of September 2, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed price pricing and represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government. The place of performance is located...
- The Defense Logistics Agency awarded a delivery order valued at $1,270.51 to AmerisourceBergen Drug Corp for Phenobarbital 65 mg/mL vials, with an ultimate completion date of September 22, 2025. This is a firm fixed-price, non-set-aside contract with a place of performance in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Phenobarbital 130 mg/mL vials valued at $6,052.44. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for ultimate completion by August 5, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ0ZEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,019.16 to AmerisourceBergen Drug Corp for the supply of Phenobarbital 130 mg/mL vials. This non-set-aside, competitively awarded contract employs firm fixed pricing and was executed on April 24, 2025, with an ultimate completion date of April 25, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. As a prime vendor for the Defense Logistics Agency's Medical Supply Chain, AmerisourceBergen supplies a broad range of pharmaceutical products and medical commodities to support military and federal healthcare systems worldwide. The Phenobarbital order supports DLA's ongoing medical supply requirements, with the agency planning to transition to next-generation Pharmaceutical Prime Vendor Global Program Generation V contracts involving multiple regional awards among different contractors.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 4/24/25 |